FMP

FMP

Enter

FREQ - Frequency Therapeuti...

photo-url-https://images.financialmodelingprep.com/symbol/FREQ.png

Frequency Therapeutics, Inc.

FREQ

NASDAQ

Inactive Equity

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

0.3 USD

0.0136 (4.54%)

Operating Data

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

179.66M

292.87M

254.1M

157.76M

99.21M

92.94M

87.08M

81.58M

76.43M

71.6M

Revenue %

-

63.01

-13.24

-37.91

-37.12

-6.31

-6.31

-6.31

-6.31

Ebitda

52.27M

113.72M

98.16M

28.51M

-

23.17M

21.7M

20.33M

19.05M

17.85M

Ebitda %

29.1

38.83

38.63

18.07

-

24.93

24.93

24.93

24.93

Ebit

49.77M

111.22M

96.06M

26.71M

-3.3M

21.76M

20.39M

19.1M

17.9M

16.77M

Ebit %

27.7

37.98

37.8

16.93

-3.33

23.42

23.42

23.42

23.42

Depreciation

2.51M

2.5M

2.1M

1.8M

3.3M

1.4M

1.31M

1.23M

1.15M

1.08M

Depreciation %

1.4

0.85

0.83

1.14

3.33

1.51

1.51

1.51

1.51

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep